Live Breaking News & Updates on Chemomab therapeutics ltd

Stay informed with the latest breaking news from Chemomab therapeutics ltd on our comprehensive webpage. Get up-to-the-minute updates on local events, politics, business, entertainment, and more. Our dedicated team of journalists delivers timely and reliable news, ensuring you're always in the know. Discover firsthand accounts, expert analysis, and exclusive interviews, all in one convenient destination. Don't miss a beat — visit our webpage for real-time breaking news in Chemomab therapeutics ltd and stay connected to the pulse of your community

Chemomab Therapeutics to Report First Quarter 2024 Financial Results and Provide a Business Update

TEL AVIV, Israel, April 24, 2024 (GLOBE NEWSWIRE) -- Chemomab Therapeutics Ltd. (Nasdaq: CMMB), (Chemomab), a clinical stage biotechnology company developing innovative therapeutics for fibro-inflammatory diseases with high unmet need,

Israel , Barbara-lindheim , Chemomab-therapeutics-ltd , Strategic-communications , Nasdaq , Vice-president , Public-relations , Region ,

Chemomab Reports New Peer-Reviewed Publication Reinforcing the Clinical Association of Its CCL24 Target with Disease Severity and Mortality in Patients with Systemic Sclerosis

Chemomab Reports New Peer-Reviewed Publication Reinforcing the Clinical Association of Its CCL24 Target with Disease Severity and Mortality in Patients with Systemic Sclerosis
marketscreener.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from marketscreener.com Daily Mail and Mail on Sunday newspapers.

United-kingdom , Israel , Rebeccal-ross , Adi-mor , Barbara-lindheim , Nasdaq , University-of-leeds , Scleroderma-programme , Arthritis-care-research , Leeds-institute-of-rheumatic , Strategic-communications , Chemomab-therapeutics-ltd

Chemomab Awarded New European Patent for CM-101, Its

Chemomab has gained a new EU patent for CM-101 covering its use in liver diseases including PSC, adding to the robust patent estate in major territories....

China , Israel , Adi-mor , Barbara-lindheim , European-patent-office-grants-new-covering , Nasdaq , European-patent-office , Strategic-communications , Chemomab-therapeutics-ltd , Multiple-liver , Primary-sclerosing-cholangitis , Further-extends-protections-afforded

Chemomab Awarded New European Patent for CM-101, Its First-in Class Monoclonal Antibody in Phase 2 Clinical Development for Primary Sclerosing Cholangitis

—European Patent Office Grants New Patent Covering Use of CM-101 for the Treatment of Multiple Liver Diseases including Primary Sclerosing Cholangitis— —Further Extends Protections Afforded by...

China , Israel , Adi-mor , Barbara-lindheim , European-patent-office-grants-new-covering , Nasdaq , European-patent-office , Strategic-communications , Chemomab-therapeutics-ltd , Multiple-liver , Primary-sclerosing-cholangitis , Further-extends-protections-afforded

Chemomab Therapeutics (NASDAQ:CMMB) Issues Earnings Results

Chemomab Therapeutics (NASDAQ:CMMB – Get Free Report) released its quarterly earnings results on Thursday. The company reported ($0.26) EPS for the quarter, beating analysts’ consensus estimates of ($0.40) by $0.14, Zacks reports. During the same period in the previous year, the firm earned ($0.72) earnings per share. Chemomab Therapeutics Stock Performance Shares of CMMB stock […]

Roth-mkm , Chemomab-therapeutics-ltd , Renaissance-technologies , Boothbay-fund-management , Chemomab-therapeutics-company-profile , Citadel-advisors , Envestnet-asset-management-inc , Chemomab-therapeutics , Get-free-report , Sigma-investments , Fund-management , Envestnet-asset-management

Chemomab Therapeutics (NASDAQ:CMMB) Announces Earnings Results

Chemomab Therapeutics (NASDAQ:CMMB – Get Free Report) issued its earnings results on Thursday. The company reported ($0.26) EPS for the quarter, beating analysts’ consensus estimates of ($0.40) by $0.14, Zacks reports. During the same period in the previous year, the company posted ($0.72) earnings per share. Chemomab Therapeutics Stock Down 3.1 % Shares of NASDAQ:CMMB […]

Roth-mkm , Renaissance-technologies , Nasdaq , Citadel-advisors , Boothbay-fund-management , Chemomab-therapeutics-company-profile , Envestnet-asset-management-inc , Chemomab-therapeutics-ltd , Chemomab-therapeutics , Get-free-report , Therapeutics-stock-down , Asset-management

Chemomab Therapeutics (CMMB) Awarded New Patents for CM-101, Its First-in Class Monoclonal Antibody in Clinical Development for Fibro-Inflammatory Diseases

Chemomab Therapeutics (CMMB) Awarded New Patents for CM-101, Its First-in Class Monoclonal Antibody in Clinical Development for Fibro-Inflammatory Diseases
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

Brazil , Israel , Israeli , Brazilian , Adi-mor , Chemomab-therapeutics-ltd , European-union , Nasdaq , Chemomab-therapeutics , Patent-offices , That-recognize-additional , Chief-executive-officer

Chemomab Awarded New Patents for CM-101, Its First-in Class Monoclonal Antibody in Clinical Development for Fibro-Inflammatory Diseases

Chemomab Therapeutics Ltd. (Nasdaq: CMMB), (Chemomab), a clinical stage biotechnology company developing innovative therapeutics for fibro-inflammatory diseases with high unmet need, today announced that the Patent Offices in Brazil and Israel have granted new patents for CM-101, Chemomab's first-in-class monoclonal antibody that neutralizes CCL24, a novel disease target that has been shown to play a critical role in the processes that drive diseases involving fibrosis and inflammation. CM-101 i

Israel , Brazil , Brazilian , Israeli , Adi-mor , Barbara-lindheim , Strategic-communications , European-union , Chemomab-therapeutics-ltd , That-recognize-additional , Chief-executive-officer , Chief-scientific-officer

Biotech Shares Massively Bid Up Before Opening Bell

Real-time index price for S&P 500 Value (IVX), along with buy or sell indicators, analysis, charts, historical performance, news and more

Tel-aviv , Israel , Brazil , Chemomab-therapeutics-ltd , Nasdaq , Patent-offices , Chemomab-therapeutics , Therapeutics-ltd , S-ampp-500-value , Ivx , S-ampp-500-value-analysis

What's Going On With Chemomab Therapeutics On Tuesday? - Chemomab Therapeutics (NASDAQ:CMMB)

Chemomab Therapeutics' CM-101 granted new patents in Brazil and Israel, currently in Phase 2 SPRING trial for primary sclerosing cholangitis. Topline data readout expected by mid-2024.

Brazil , Israel , Brazilian , Israeli , Chemomab-therapeutics-ltd , Therapeutics-ltd , Chemomab-therapeutics , Patent-offices , Orphan-drug ,